Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition
Triple-Negative Breast Cancer (TNBC) is a clinical subtype where aberrant expression of receptor tyrosine kinases (RTKs) leads to the activation of the RAS-RAF-MEK-ERK pathway contributing to tumor progression. Therapies targeting components of the RAF-MEK-ERK pathway in TNBC have been disappointing due to rapid onset of adaptive reprogramming of the RTK landscape leading to pathway reactivation.…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
